Press Releases Subscribe to our News
20. Oktober 2022
19. Oktober 2022
Non-Regulatory
Biosergen allocates shares to an underwriter in connection with the completed rights issue
Release
05. Oktober 2022
26. September 2022
15. September 2022
Non-Regulatory
The subscription period in Biosergen’s rights issue starts today
14. September 2022
13. September 2022
Non-Regulatory
Biosergen AB: Biosergen publishes prospectus due to rights issue of units
ReleaseEU-tillväxtprospekt - Biosergen
11. Juli 2022
Non-Regulatory
3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.
Release
25. Mai 2022
02. Mai 2022
Non-Regulatory
Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus.
Release
19. April 2022
Non-Regulatory
The first subjects dosed successfully with no adverse events in the phase I trial of BSG005
Release
24. August 2021
Non-Regulatory
Biosergen’s application to start human clinical trials with BSG005 is approved
Release
19. August 2021
23. Juni 2021
Non-Regulatory
BIOSERGEN HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM.
Biosergen listing approval
31. Mai 2021
Non-Regulatory
The outbreak of mucormycosis (the so-called “Black Fungus”) in India is a prime example of the great need for a safer antifungal drug with true fungicidal activity
Release
19. Mai 2021
Non-Regulatory
BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM
BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)Non-Regulatory
